[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"headache\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:headache":703},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,37,0,25,[9,45,71,93,131,153,175,200,221,271,289,327,352,374,399,420,457,494,518,541,576,602,627,650,676],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100643724",false,"NCT07629141","Muscle Position and Dry Needling Efficacy","The Importance of Muscle Position in the Effectiveness of Dry Needling Technique","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Neck pain lasting more than 3 months\n* Current neck pain greater than 3\u002F10 on the VAS (Visual Analog Scale)\n* Presence of active trigger points in the upper trapezius muscle, meeting the following criteria: Painful point within a taut band whose palpation reproduces the patient's symptoms.\n\nExclusion Criteria:\n\n* Neck pain with a medical diagnosis (fractures, arthritis, fibromyalgia, etc.)\n* Radicular pain (paresthesia, burning, electric shocks)\n* Whiplash or any recent trauma\n* Previous surgery\n* Treatment by another physiotherapist within the last 3 months\n* Infections\n* Needle phobia\n* Use of anticoagulant medications\n* Pregnancy\n* Fibromyalgia\n* Metal allergies\n* Cognitive deficits or communication problems","ALL","18 Years","80 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","Currently, no previous studies have investigated how the position of a muscle before dry needling may influence the outcome and effectiveness of the treatment.\n\nThis study aims to demonstrate whether the position of the upper trapezius muscle during dry needling treatment influences the outcome of that treatment in subjects with neck pain.\n\nA total of 46 participants with chronic neck pain will be recruited and randomly assigned to two groups: a dry needling group with the muscle in a stretched position and a dry needling group with the muscle in a shortened position. A total of two treatment sessions will be performed, separated by a 7-day interval. The primary outcome measure will be the intensity of neck and head pain, measured using the visual analog scale (VAS). Other variables to be measured include the cervical disability index, kinesiophobia, and catastrophizing (using a self-completion questionnaire), as well as participants' expectations and post-needling pain.",[27,28],"Neck Pain","Headache",[30,31],"dry needling","Musculoskeletal Pain","RECRUITING","2026-06-29",{"date":35,"type":36},"2026-07-01","ACTUAL",{"date":38,"type":36},"2026-06-08",{"date":40,"type":21},"2026-12-15",{"name":42,"class":43},"University of Alcala","OTHER",2,{"id":46,"slug":4,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100641552","NCT07661758","Intravenous Lidocaine to Prevent Post-Fundal Pressure Headache During Cesarean Section","Pre-emptive Single Intravenous Lidocaine Dose to Prevent Post-Fundal Pressure Headache During Cesarean Section: The LID-HEAD Multi-center Randomized Controlled Trial","LID-HEAD","Inclusion Criteria:\n\n* Aged ≥ 18 years\n* American Society of Anesthesiologists (ASA) Physical Status II\n* Scheduled for elective cesarean section under spinal anesthesia\n\nExclusion Criteria:\n\n* Patients declined to participate in the trial,\n* Patients with history of any type of headache, mental illness, or cerebrovascular diseases\n* Previous epidural insertion for painless labor or any other indications;\n* Patients on opioid or analgesic medications;\n* Those with pregnancy-induced hypertension or diabetic patients,\n* Allergy to lidocaine;\n* Contraindication or failure of spinal anesthesia.","FEMALE",{"count":54,"type":21},680,[56],"PHASE3","This prospective randomized controlled multicenter study will be conducted to evaluate the effects of pre-emptive IV lidocaine dose on the incidence and severity of intraoperative headache that may occur after the extra-abdominal manual uterine fundal pressure in patients undergoing cesarean section under spinal anesthesia.",[59,60,28],"Intravenous Lidocaine","Fundal Pressure","NOT_YET_RECRUITING","2026-06-16",{"date":64,"type":36},"2026-06-22",{"date":35,"type":21},{"date":67,"type":21},"2026-11-02",{"name":69,"class":43},"Tanta University",1,{"id":72,"slug":4,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":70},"100533438","NCT06225817","Placebo Impacts Sleep and Pain Modulation in Chronic Pain","The Impact of Open-label Placebo on Sleep and Pain Modulation","Inclusion Criteria:\n\n* Age ( 18-88 years old)\n* English speaker (written and spoken)\n* TMD for at least 3 months\n* Grade Chronic Pain Scale (GCPS) ≥1\n* Smartphone\u002Ftext messaging capability\n\nExclusion Criteria:\n\n* Present or past degenerative neuromuscular disease\n* Cardiovascular, neurological diseases, pulmonary abnormalities, kidney disease, liver disease, history of cancer within past 3 years\n* Any personal (or family first degree) history of mania, schizophrenia, or other psychoses\n* Severe psychiatric condition (e.g. schizophrenia, bipolar disorders, autism) leading to hospitalization within the last 3 years.\n* Lifetime alcohol\u002Fdrug dependence or alcohol\u002Fdrug abuse in past 3 months\n* Pregnancy or breast feeding\n* Impaired or uncorrected hearing","88 Years",{"count":79,"type":21},111,[24],"The goal of this free-choice parallel design clinical trial is to examine the potential beneficial effects of using open-label placebo (OLP) in improving chronic pain related outcomes and sleep quality in people with temporomandibular disorders. This study will enroll a cohort of participants with temporomandibular disorders (TMD) which lasts for more than 3 months. The main questions it aims to answer are:\n\n1. Will participants with TMD be more likely to take open-label placebo pills if they are introduced to the effects of placebo (e.g., going through an expectation management session)?\n2. Will taking open-label placebo plus expectation management improve chronic pain related outcomes, such as chronic pain intensity, interference, levels of anxiety and depression, in the cohort of TMD?\n3. Will open-label placebo plus expectation management improve sleep quality in participants suffering from TMD?\n\nTo answer the above questions, participants with TMD will be randomly assigned to three groups: 1. Open-label placebo plus expectation management group, where participants will complete a 1-hour discussion session about their expectations toward open-lable placebo intervention, and then take 1 open-labe placebo pill per day for a total of 45 days. 2. Open-label placebo only group where participants will be asked to take open-label placebo pills, one pill per day, for a total of 45 days. 3. standard of care group where participants will maintain their usual care without introducing open-label placebo to them during the 45 days monitoring. Researchers will compare the chronic pain intensity, interference, mood, anxiety, and sleep quality between the open-label placebo group and the wait-list group. Daily chronic pain will be measured using visual analog scale (VAS) ranging from 0=no pain at all to 100=maximum tolerable pain. Chronic pain interference using Patient-Reported Outcomes Measurement Information System (PROMIS) pain interference and pain behavior. Anxiety and depression will be measured using PROMIS-anxiety, and PROMIS-depression scales respectively. Finally, sleep quality will be quantified using the objective measurement Motion Watch during the 45 days intervention and monitoring. In order to have a rigorous measurement of the baseline pain and sleep fluctuation, this study will include a 7-day phenotyping period before the starting of the 45-day intervention and monitoring. During the 7-day phenotyping period, participants will record their daily chronic pain and sleep quality using polysomnography.",[83,28],"Chronic Pain","2026-06-15",{"date":86,"type":36},"2026-06-17",{"date":88,"type":36},"2025-04-21",{"date":90,"type":21},"2028-07-30",{"name":92,"class":43},"University of Maryland, Baltimore",{"id":94,"slug":4,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":102,"briefSummary":103,"conditions":104,"keywords":112,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":44},"100417438","NCT04715685","Mind Body Balance for Pediatric Migraine","Inclusion Criteria:\n\n* Diagnosis: Migraine with or without aura or chronic migraine that meets the International Classification of Headache Disorders(ICHD) criteria\n* Frequency: Headache frequency based upon prospective headache diary of 28 days must be ≥ 4 and ≤ 28.\n* PedMIDAS: PedMIDAS Disability Score \\> 4, indicating at least mild disruption in daily activities and \\\u003C 140, indicating extreme disability that may require more comprehensive, multi-component therapy\n* Use of one or more of the following prescribed nutraceuticals and\u002For preventive anti-migraine medications at the time or randomization or be on a stable dose of one or more of the following throughout the 12 weeks of the study \\[Vitamin B2 (Riboflavin), Co-Q 10 (Coenzyme Q10), Magnesium (Mg), Vitamin D2 or D3 (Erocalciferol\u002FCholecalciferol), Depakote (Divalproate), Inderal (Propanerol), Elavil ((Amitripyline), Topamax (Topiramate), Periactin (Cyproheptadine)\\]\n* Language: English speaking, able to complete interviews and questionnaires in English\n\nExclusion Criteria:\n\n* Continuous migraine defined as unrelenting headache for a 28 day period\n* Must agree not to take non-specific acute medication, such as NSAIDS (e.g., ibuprofen), more than 3 times per week, or migraine specific acute medications, such as triptans, more than 6 times per month (to prevent medication overuse headache)\n* PedMIDAS Disability Score \\> 140, indicating extreme disability that may require more comprehensive, multi-component therapy\n* Youth who are pregnant, or those who are sexually active and not using a medically accepted form of contraception (barrier or hormonal methods)\n* Present severe psychiatric disease, alcohol or drug dependence, or documented developmental delays or impairments (e.g., autism, cerebral palsy, or mental retardation) or other circumstances, that, in the opinion of the investigator, would interfere with adherence to study requirements or safe participation in the study","10 Years","17 Years",{"count":101,"type":21},260,[24],"This study uses a factorial research design to evaluate a nurse delivered mind body intervention using different doses of 3 treatment components to determine the optimized treatment for headache day reduction.",[28,105,106,107,108,109,110,111],"Headache Disorders","Headache, Migraine","Migraine","Migraine Disorders","Migraine With Aura","Migraine Without Aura","Chronic Migraine",[113,114,115,116,117,118,119,120,121,122],"headache","migraine","cognitive behavioral therapy","pediatrics","mind body intervention","diaphragmatic breathing","progressive muscle relaxation","imagery","relaxation","biofeedback","2026-06-14",{"date":62,"type":36},{"date":126,"type":36},"2021-03-09",{"date":128,"type":21},"2026-11-30",{"name":130,"class":43},"Children's Hospital Medical Center, Cincinnati",{"id":132,"slug":4,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":143,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":70},"100529169","NCT06170281","Sequential, Multiple Assignment, Double Randomized Preference, Migraine Behavioral Trial","A Feasibility Clinical Trial Assessing Patient Preference, Optimum Combinations and Sequences of a Multicomponent, Virtually-Delivered Migraine Behavioral Intervention","SMARTMig","Inclusion Criteria:\n\n* have chronic migraine for a minimum of 1-year\n* aged 18 years and older\n\nExclusion Criteria:\n\n* secondary headache disorders\n* children younger than 18 years old",{"count":139,"type":21},24,[24],"This study will unpack the behavioral intervention for migraine and determine the optimum combinations. In addition, the study will test preference and self-selection effects during the trial.",[107,28,111,105],[114,113,144],"behavioral intervention","2026-06-12",{"date":62,"type":36},{"date":148,"type":21},"2026-12",{"date":150,"type":21},"2028-12-01",{"name":152,"class":43},"Mayo Clinic",{"id":154,"slug":4,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":70},"100471142","NCT05415020","Determining the Utility of a Behavioral Intervention in Chronic Migraine","Feasibility, Acceptability, and Pilot Testing of a Behavioral Intervention for Chronic Migraine","RLB","Inclusion Criteria:\n\n* have chronic migraine for a minimum of 1-year\n* aged 18 years and older\n\nExclusion Criteria:\n\n* other headache disorders including secondary headache disorders\n* children younger than 18 years old\n* current pregnancy",{"count":161,"type":21},60,[24],"This proposal will involve a pilot study to evaluate the feasibility, acceptability, and outcomes of a lifestyle behavior protocol in managing chronic migraine. Additionally, the proposal will investigate biomolecules that are uniquely involved in chronic migraine patients who respond to the protocol. Successful completion of this proposal will inform the design of a future full-scale behavioral clinical trial to control chronic migraine.",[107,28,108,111,165,105],"Lifestyle Factors",[108,28,167],"Lifestyle","2026-06-04",{"date":38,"type":36},{"date":171,"type":36},"2022-06-29",{"date":173,"type":21},"2027-07-31",{"name":152,"class":43},{"id":176,"slug":4,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":22,"phases":183,"briefSummary":185,"conditions":186,"keywords":188,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":70},"100601892","NCT07116408","Intranasal Sphenopalatine Ganglion Blockade for Headaches Following Aneurysmal Subarachnoid Hemorrhage","Intranasal Sphenopalatine Ganglion Blockade as a Non-invasive, Opioid-sparing Treatment for Headaches Following Aneurysmal Subarachnoid Hemorrhage","Inclusion Criteria:\n\n• Patients aged 18 years or older who are being treated in the neurologic ICU for subarachnoid hemorrhage with Hunt and Hess scale of 0-3 (Scale ranges from 0 to 5 with higher numbers indicating more severe symptoms) and able to verbally report headache will be considered for inclusion in this study.\n\nExclusion Criteria:\n\n* Patients under the age of 18 years of age.\n* Patients with an allergy to lidocaine.\n* Patients from all vulnerable groups.\n* Patients with Hunt and Hess scale score of 4-5. (Scale ranges from 0 to 5 with higher numbers indicating more severe symptoms.)\n* Patients who are not able to consent.\n* Mentally impaired patients that are unable to provide consent.\n* Patients that are prisoners.\n* Pregnant patients.\n\nAdditionally, patients with contraindications to use of the Tx 360 device will be excluded. Contraindications include:\n\n* History of recurrent nose bleeds.\n* Nasal septal deformity such as cleft lip and palate, choanal atresia (narrowed nasal passages), atrophic rhinitis, rhinitis medicamentosa, septal perforation, nasal\u002Fmidface trauma.\n* Recent nasal\u002Fsinus surgery\n* Presence of a bleeding disorder (eg., Von Willebrand's disease or hemophilia).\n* Severe respiratory distress.\n* Presence of angiofibroma, sinus tumor, or granulomatous disease of the nasopharynx.\n* Presence of nasal trauma.\n* Nasal congestion that has been present more than 10 days, high fever, or abnormal appearance of the nasal mucosa or mucus.",{"count":182,"type":21},20,[184],"PHASE4","In patients with bleeding from a brain aneurysm, severe headache is the most common complaint. However, the pain is difficult to treat. The use of standard pain medications is common, but pain control remains poor. Additionally, pain medicines have multiple side effects including sedation, interference with breathing, intestinal cramping, low blood pressure, and the risk of addiction. In the present study, the investigators will examine the use of a medication to block the sphenopalatine ganglion which is a bundle of nerves that includes nerves that cause head pain. This block is performed by spraying numbing medication into the back of the nasal cavity on both sides. This particular pain medication does not have the side effects discussed above. The purpose of the study is to see if this treatment will decrease pain without causing unwanted side effects.\n\nAll patients in the study will receive standard pain medicine as needed for headache. Information will be collected from the patient's medical chart on the amount of pain medication used and the amount of pain the patient describes having. The average pain will be calculated for the first 24 hours the patient is in the hospital. At that point, the patient will receive pain medication sprayed into the back of the nasal cavity on both sides. Patients will also receive this treatment 3 days later. Following these treatments, information will be obtained on the average amount of pain, and how much other pain medication is used.\n\nThe investigators will look at the amount of pain and the amount of other pain medicine used over the first 24 hours before the nasal pain medicine treatment and compare it to the time after the treatments to see if the amount of pain decreases and if the amount of other pain medicine needed decreases as well. Six months after discharge, the patient will be contacted by phone to find out more information about how much head pain they had after discharge from the hospital.",[187,28],"Aneurysmal Subarachnoid Hemorrhage (aSAH)",[28,189,190],"subarachnoid hemorrhage","aneurysm","2026-05-21",{"date":193,"type":36},"2026-05-27",{"date":195,"type":36},"2024-05-20",{"date":197,"type":21},"2027-05",{"name":199,"class":43},"Wright State University",{"id":201,"slug":4,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":16,"minAge":205,"maxAge":206,"enrollmentInfo":207,"targetDuration":4,"studyType":22,"phases":209,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":70},"100552310","NCT06471426","The Effect of Osteopathic Treatment on Craniocervico-Mandibular Dysfunction","Inclusion Criteria:\n\n* male and female subjects 19-65 years old\n* neck pain and\u002For headaches of \\> 1 month duration\n\nExclusion Criteria:\n\n* prior cervical or thoracic spinal surgery\n* diagnosis cervical radiculopathy or pinched nerve in the neck\n* diagnosis of jaw disease or dysfunction\n* diagnosis of connective tissue or muscle disorders\n* diagnosis of cancer\n* previous spinal cord injury\n* Inflammatory arthritis and fibromyalgia\n* eye movement disorder\n* known pregnancy (hormonal changes affecting tissues could be a confounding variable)\n* tobacco use\n* known diabetes or prediabetes\n* allergy to ultrasound gel (propylene glycol)\n* history of manual therapy treatment within the past 2 weeks\n* history of injection for pain within the past month\n* currently taking muscle relaxers","19 Years","65 Years",{"count":208,"type":21},30,[24],"The goal of this clinical trial is to measure the effects of osteopathic manipulative treatment (OMT) on tissues of the craniocervico-mandibular unit (CCMU) in individuals with neck pain and headaches.\n\nThe main questions to answer are:\n\n1. How does OMT affect CCMU muscle stiffness\n2. How does OMT affect jaw motion\n3. How does OMT affect autonomic function\n4. Is pain pressure threshold affected by OMT of the CCMU\n\nParticipants will undergo the following interventions:\n\n1. Photos taken to measure head and neck angles\n2. Ultrasound\n3. Smooth Pursuit Neck Torsion Test\n4. Motion Capture\n5. Autonomic Protocol\n6. Algometry\n7. Surveys",[28,27],"2026-05-11",{"date":214,"type":36},"2026-05-14",{"date":216,"type":36},"2024-04-22",{"date":218,"type":21},"2026-09-22",{"name":220,"class":43},"Edward Via Virginia College of Osteopathic Medicine",{"id":222,"slug":4,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":52,"minAge":17,"maxAge":227,"enrollmentInfo":228,"targetDuration":4,"studyType":22,"phases":230,"briefSummary":231,"conditions":232,"keywords":243,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":70},"100571149","NCT06716489","Aerobic Exercise and Its Impact on Sensory, Musculoskeletal, and Psychosocial Aspects in Migraine","Influence of Aerobic Exercise on Sensory Perception, Musculoskeletal and Psychosocial Alterations in Patients With Migraine","Inclusion Criteria:\n\n* Women aged between 18 and 48 years.\n* Diagnosed with migraine by an experienced neurologist specialized in headaches, following the criteria of the International Classification of Headache Disorders (ICHD).\n* Frequency of headache between 3 and 8 days per month, to ensure adherence to the treatment.\n\nExclusion Criteria:\n\n* Presence of any other type of concurrent headache.\n* Medical conditions affecting sensitivity and autonomic modulation, such as peripheral neuropathies, autonomic disorders, severe neurological diseases, and others.\n* Conditions that prevent physical activity, such as severe musculoskeletal injuries, cardiovascular diseases, or related conditions.\n* Premature ovarian failure.\n* Regular physical exercise in the past year.\n* Body Mass Index (BMI) above 30.0.\n* Smokers or individuals using drugs that interfere with sensitivity and cardiac modulation (e.g., beta-blockers).\n* Abuse of abortive medications.","48 Years",{"count":229,"type":21},100,[24],"Migraine is a neurological disorder associated with high levels of disability and changes in sensory processing, musculoskeletal function, and psychosocial factors. Aerobic exercise is a low-cost, non-pharmacological strategy that has shown potential benefits for migraine management, but its effects on sensory perception and musculoskeletal function are not yet fully understood.\n\nThis randomized controlled trial will investigate the effects of a supervised aerobic exercise program combined with pain neuroscience education compared with an active control condition in women aged 18 to 48 years diagnosed with migraine. Participants will be randomly allocated to either an intervention group, which will perform supervised aerobic exercise three times per week for 16 weeks and receive one session of pain neuroscience education, or a control group, which will receive recommendations for unsupervised physical activity at home.\n\nOutcomes related to migraine-related disability, self-reported symptoms, sensory sensitivity, and musculoskeletal function will be assessed at baseline and after the intervention period. Questionnaires will also be collected at a 6-month follow-up. The results of this study may contribute to the development of accessible and low-risk non-pharmacological treatment strategies for people with migraine.",[107,233,234,235,28,236,105,237,238,239,240,241,242],"Migraine Disease","Migraine Disorder","Migraine Disorders, Brain","Headache (Migraine)","Headache Disorders, Primary","Aerobic Exercise","Pain Management","Sensory Disorders","Psychosocial Factors","Quality of Life",[114,244,245,246,113,247,248,249,250,251,252,241,253,254,255,256,257,258,259,260,261],"aerobic exercise","sensory perception","exercise","disability","musculoeskeletal alterations","quality of life","neck pain","cervical pain","Sensory Thresholds","Physical Fitness","Exercise Intervention","Central Sensitization","Physical Therapy","Migraine Management","Non-pharmacological Treatment","Clinical Trial","Headache Relief","sensitization","2026-04-27",{"date":264,"type":36},"2026-04-28",{"date":266,"type":36},"2026-03-03",{"date":268,"type":21},"2028-11-30",{"name":270,"class":43},"University of Sao Paulo",{"id":272,"slug":4,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":277,"enrollmentInfo":278,"targetDuration":4,"studyType":22,"phases":279,"briefSummary":280,"conditions":281,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":70},"100490176","NCT05662722","Percutaneous Needle Electrolysis (PNE) on the Concha of the Ear","Use of Infrared Thermography in the Measurement of Facial Blood Flow After the Application of Percutaneous Needle Electrolysis (PNE) on the Concha of the Ear","Inclusion Criteria:\n\n* Headache with a frequency of at least one monthly episode.\n* Present the \"cold nose\" and\u002For \"cold patch\" pattern\n\nExclusion Criteria:\n\n* Do not present a \"cold nose\" and\u002For \"cold patch\" pattern\n* Pregnant women\n* Subjects with facial alterations that may affect facial vascularization (sinusitis, allergies...)\n* Patients with belonephobia or allergy to metals or any material used in the procedure.","70 Years",{"count":161,"type":21},[24],"Headache is a very frequent symptom among the world population, the adult population with an active headache disorder are 46% for headache in general, 11% for migraine, 42% for tension-type headache and 3% for chronic daily headache. There are different therapeutic approaches for the improvement of headache. Transcutaneous stimulation of the auricular vagal nerve is being used for the treatment of headache due to the involvement of the vagus nerve in inflammation and pain modulation. On the other hand, galvanic current has shown a measurable effect by increasing parasympathetic activity. The objective of this clinical trial is to stimulate the auricular vagal nerve with galvanic current using a needle as an electrode that will be inserted into the concha of the ear. As a tool for measuring results, infrared thermography will be used to observe changes in facial skin temperature, since patients with high sympathetic activity present a characteristic pattern of \"cold nose\" and\u002For \"cold patch\". In addition, variables that record changes in autonomic activity such as skin conductance and heart rate variability will be collected.",[28],{"date":283,"type":36},"2026-05-01",{"date":285,"type":36},"2022-03-22",{"date":287,"type":21},"2027-12-01",{"name":42,"class":43},{"id":290,"slug":4,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":52,"minAge":17,"maxAge":295,"enrollmentInfo":296,"targetDuration":298,"studyType":299,"phases":4,"briefSummary":300,"conditions":301,"keywords":306,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":70},"100576721","NCT06788977","External Trigeminal Nerve Stimulation for Migraine Treatment in Pregnancy","CEFALY Pregnancy Registry","Inclusion Criteria:\n\n1. Patients willing and able to provide simple consent for registry participation.\n2. Has access to email, text messages via smartphone or computer with internet access\n3. Be between the ages of 18 to 44 years at enrollment.\n4. Pregnant with one fetus\u002Fbaby at time of enrollment (singleton pregnancy)\n5. Have headaches or migraines prior to pregnancy and continued to have headaches or migraines into pregnancy OR headaches or migraines began while pregnant in the first trimester.\n6. Able to provide proof of active intrauterine pregnancy and estimated due date, via online document upload, using any of the following documents:\n\n   1. ultrasound report of current pregnancy\n   2. beta hcg lab report\n   3. a signed provider's medical documentation confirming intrauterine pregnancy with fetal heart sounds and estimated due date\n   4. a signed provider's note on a prescription sheet or physician letterhead confirming intrauterine pregnancy and estimated due date\n\nExclusion Criteria:\n\n1. Patients under the age of 18 or over the age of 44 at enrollment\n2. Not pregnant at time of enrollment\n3. Pregnant with more than one fetus\u002Fbaby at time of enrollment (multigestational pregnancy)\n4. Patients with any other condition which might preclude participation in the opinion of the patient's physician(s) or the study's principal investigator\n5. No access to email, smartphone, or computer with internet access","44 Years",{"count":297,"type":21},550,"12 Months","OBSERVATIONAL","This online registry aims to understand the potential benefits and safety of external trigeminal nerve stimulation for the treatment of migraine in pregnant women. Women do not need to use external trigeminal nerve stimulation or any other form of migraine treatment to participate in the registry.\n\nThe main question it aims to answer is:\n\nIs external trigeminal nerve stimulation a safe and effective option for migraine treatment during and after pregnancy?\n\nThere are no required changes in migraine treatment to participate in this registry. Participants may or may not use external trigeminal nerve stimulation or any other treatment they currently use and may still participate in the registry. There are no clinic or research visits, as the registry is entirely online. Participants will be asked to complete up to six 15- 20-minute surveys over a time period of up to 12 months.",[302,107,28,303,304,305],"Pregnancy","Postpartum","Depression","Anxiety",[302,107,28,307,308,309,303,310,311,312,313,314,315,316],"Neuromodulation","Trigeminal Nerve Stimulation","External Trigeminal Nerve Stimulation","drug-free","medications","complementary therapy","alternative therapy","wholistic therapy","natural","non-invasive device","2026-04-13",{"date":319,"type":36},"2026-04-15",{"date":321,"type":36},"2024-11-25",{"date":323,"type":21},"2030-12",{"name":325,"class":326},"Cefaly Technology","INDUSTRY",{"id":328,"slug":4,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":206,"enrollmentInfo":333,"targetDuration":4,"studyType":22,"phases":335,"briefSummary":336,"conditions":337,"keywords":340,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":70},"100617968","NCT07325513","Machine Learning in Guiding rTMS Treatment for GWI-Related Headaches and Body Pain","SVM - GWI","Inclusion Criteria:\n\n* Male or female\n* Veteran or active military personnel\n* Between the ages of 18 and 65 years old\n* Served in the Persian Gulf region for at least 30 consecutive days between August 1, 1990, and July 31, 1991\n* Meets the CDC Criteria for GWVI (GWI), with symptoms starting during or after the 1990-1991 Persian Gulf deployment. Symptoms must be present for at least 6 months prior to enrollment in the study. Symptoms must be present in at least 2 of the 3 categories of fatigue, musculoskeletal, and mood cognitive.\n* Meets the Kansas Criteria for GWVI (GWI), with symptoms starting during or after the 1990-1991 Persian Gulf deployment. Symptoms must be present for at least 6 months prior to enrollment in the study. Qualifying symptoms must be at least moderate in severity and\u002For multiple symptoms must be present within at least 3 of 6 categories consisting of fatigue\u002Fsleep, neurological\u002Fcognitive\u002Fmood, pain, respiratory, gastroenterological, and dermatological symptomology.\n* Average Overall Daily Muscle Pain Intensity ≥3 on a 0-10 NPRS, present for at least 6 months\n* Average Overall Daily Extremities Joint Pain Intensity ≥3 on a 0-10 NPRS, present for at least 6 months\n* Average Headache Exacerbation Intensity ≥3 on a 0-10 NPRS, with headaches occurring for at least 6 months\n* Headache Exacerbation\u002Fattack ≥ 1 time per week with the average intensity ≥3 on a 0-10 NPS, lasting \\> 1 hour in the past three months\n* International Headache Society Criteria for Migraine Headache without aura\n\nExclusion Criteria:\n\n* Children under the age of 18\n* Pregnant women\n* Individuals with cognitive\u002Fdecisional impairment\n* Non-English speaking individuals\n* Prisoners of War\n* Incarcerated individuals\n* VA employees - including VA paid, IPA, or WOC\n* Students of the institution or of the investigator\n* Patients with cancer\n* History of pacemaker implant\n* Presence of ferromagnetic material (e.g., bullet fragment, shrapnel, device implant) in the brain or body that will prohibit the patients from having a brain MRI\n* History of dementia, major psychiatric diseases, or life-threatening diseases\n* Presence of any other chronic neuropathic pain states such as Complex Regional Pain Syndrome or Painful Peripheral Neuropathy\n* Known diagnosis of moderate to severe osteoarthritis and\u002For rheumatologic joint pain prior to the GWI deployment\n* Low back pain with mechanical origins such as lumbar radiculopathy or radiculitis or lumbar facet arthropathy\n* Concurrent conditions, like lupus, that can produce symptoms compatible with GWVI\n* History of seizure\n* Pending litigation\n* History of Traumatic Brain Injury-related headaches\n* Chronic Tension or Cluster Headache. However, subjects with occasional tension headaches (less than once every three months and lasting no more than 24 hours) will not be excluded from the study.\n* Ongoing Cognitive Rehabilitation or Treatment of PTSD\n* Recent exacerbation of anxiety disorder symptoms, active substance dependence, and\u002For current psychotic symptoms\n* Ongoing suicidal\u002Fhomicidal ideation or recent (in the past 6 months) suicidal attempts\n* Patients who receive any narcotic-based analgesic, topical analgesics over the affected site, steroid and local anesthetic injection, anticonvulsants, and antipsychotic medications less than 7 days prior to the pretreatment assessment\n* Patients who do not agree to avoid use of non-pharmacologic treatments, including but not limited to, transcutaneous electrical nerve stimulation unit (TENS), acupuncture, acupressure, and therapeutic massage during the entire study.\n* Patients who do not agree to use additional acetaminophen (up to a maximum total of 3g per day) as the only rescue medication\n* Patients who have received rTMS within the past 6 months",{"count":334,"type":21},140,[24],"The goal of this clinical trial is to create a machine learning algorithm to improve active repetitive transcranial magnetic stimulation (rTMS) treatments for veterans and\u002For active military personnel by alleviating Gulf War Illness related headaches and body pain (GWI-HAP). This study aims to develop and validate a Support Vector Machine (SVM) model that could replace the trial-and-error process by assessing functional connectivity provided by resting state functional magnetic resonance imaging (rs-fMRI) data to predict the most effective rTMS protocol for each person. All participants will be receiving active rTMS treatment.\n\nThe main questions it intends to answer are:\n\n1. Does the SVM model predict a more effective treatment response rate for predicted respondents undergoing active rTMS at the left dorsolateral prefrontal cortex (DLPFC) compared to predicted non-respondents?\n2. Does the SVM model predict a more effective treatment response rate while undergoing active rTMS at the left dorsolateral prefrontal cortex (DLPFC) and left motor cortex (LMC) in predicted respondents compared to predicted non-respondents?\n\nParticipants will undergo the following:\n\n1. Receive a total of 13 active rTMS treatment sessions over 3-4 months.\n2. Visit the clinic for a total of 15 visits for assessments, check ups, and treatments.\n3. Keep a daily log of their headaches, muscle and joint pain throughout the study.",[338,28,339],"Gulf War Illness","Muscle and Joint Pain",[341,342,28,343,339],"Repetitive Transcranial Magnetic Stimulation (rTMS)","Support Vector Machine (SVM)","Machine Learning","2026-04-08",{"date":317,"type":36},{"date":347,"type":36},"2026-03-25",{"date":349,"type":21},"2029-10",{"name":351,"class":43},"Veterans Medical Research Foundation",{"id":353,"slug":4,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":206,"enrollmentInfo":358,"targetDuration":4,"studyType":299,"phases":4,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":369,"leadSponsor":371,"locationsCount":70},"100630436","NCT07487649","Treatment Response in Patients With Medication-Overuse Headache","Factors Affecting Treatment Response in Patients With Medication-Overuse Headache Undergoing Greater Occipital Nerve Blockade","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Diagnosis of medication-overuse headache according to the International Classification of Headache Disorders, 3rd edition (ICHD-3)\n* Diagnosis of medication-overuse headache associated with the use of triptans or nonsteroidal anti-inflammatory drugs\n* Previous diagnosis of chronic migraine or chronic tension-type headache according to the ICHD-3 criteria\n\nExclusion Criteria:\n\n* History of severe head or neck trauma or previous neurosurgical intervention\n* Presence of a severe psychiatric disorder (e.g., severe depression, schizophrenia)\n* History of infectious disease, chronic inflammatory disease, or malignancy\n* Previous diagnosis of secondary headache\n* History of substance abuse\n* Pregnancy or breastfeeding\n* History of an additional neurological disorder (e.g., cerebrovascular disease, multiple sclerosis)\n* Difficulty with cooperation\n* Presence of a concomitant systemic disease that may affect quality of life (e.g., congestive heart failure, chronic kidney disease, chronic liver disease, pulmonary disease, uncontrolled diabetes, or peripheral vascular disease)",{"count":359,"type":21},70,"The aim of this study to evaluate pre-injection patient-related factors that may influence treatment response in patients with medication-overuse headache who underwent ultrasound-guided greater occipital nerve block.",[362,363,28,364],"Medication-overuse Headache","Treatment","Greater Occipital Nerve Block","2026-03-17",{"date":367,"type":36},"2026-03-23",{"date":365,"type":36},{"date":370,"type":21},"2026-05-30",{"name":372,"class":373},"Sultan 1. Murat State Hospital","OTHER_GOV",{"id":375,"slug":4,"hasResults":11,"nctId":376,"briefTitle":377,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":380,"targetDuration":4,"studyType":22,"phases":382,"briefSummary":383,"conditions":384,"keywords":387,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":70},"100629777","NCT07479082","Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation for Postoperative Headache Following Stent-Assisted Coiling of Unruptured Intracranial Aneurysms","IMPACT-HT","Inclusion Criteria:\n\n1. Age 18-80 years\n2. Diagnosed with unruptured intracranial aneurysm confirmed by imaging\n3. Planned to undergo stent-assisted coiling or flow diverter embolization\n4. Signed informed consent\n\nExclusion Criteria:\n\n1. History of SAH, ICH, brain tumor, major trauma, substance abuse, syncope, or seizures\n2. Recurrent\u002Ftraumatic\u002Finfectious\u002Fmyxomatous aneurysms\n3. Primary headache disorders (e.g., migraine, cluster headache, trigeminal neuralgia) not attributed to UIA\n4. Previous vagotomy, migraine surgery, or implanted neurostimulators\n5. Other concurrent electronic\u002Fimplantable devices (e.g., pacemakers, neurostimulators)\n6. Clinically significant hypotension, congenital heart disease, severe arrhythmia, unstable angina, or recent MI\n7. Inability to follow up due to severe psychiatric disorder or refusal\n8. Skin lesions at taVNS placement site\n9. Pregnant or lactating\n10. Participation in other trials",{"count":381,"type":21},440,[24],"The goal of this clinical trial is to evaluate the efficacy and safety of transcutaneous auricular vagus nerve stimulation (taVNS) in reducing postoperative headache among adults undergoing stent-assisted coiling for unruptured intracranial aneurysms (UIAs). The study will include male and female participants aged 18 to 80 years who are scheduled for endovascular treatment of UIAs with stent-assisted coiling or flow diverter devices.\n\nThe main questions it aims to answer are:\n\n* Can taVNS reduce the incidence of headache within 90 days after stent-assisted embolization of UIAs?\n* Is taVNS safe and well-tolerated in this patient population? Researchers will compare patients receiving active taVNS to those receiving sham stimulation to determine if taVNS leads to fewer postoperative headaches and reduced need for analgesic medications.\n\nParticipants will:\n\n* Wear a taVNS device on the left earlobe (active group) or cymba conchae (sham group) starting 1 day before the procedure\n* Receive 30-minute stimulation sessions, twice daily, until postoperative day 5\n* Undergo follow-up assessments of headache occurrence, pain intensity, analgesic use, and any adverse events through day 90 after the procedure",[385,28,386],"Unruptured Intracranial Aneurysm","Vagus Nerve Stimulations",[385,388,389],"Postoperative Headache","Vagus Nerve Stimulation","2026-03-13",{"date":392,"type":36},"2026-03-18",{"date":394,"type":36},"2025-09-30",{"date":396,"type":21},"2027-07",{"name":398,"class":43},"Beijing Tiantan Hospital",{"id":400,"slug":4,"hasResults":11,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":11,"sex":16,"minAge":98,"maxAge":99,"enrollmentInfo":405,"targetDuration":4,"studyType":22,"phases":407,"briefSummary":408,"conditions":409,"keywords":410,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":419},"100507610","NCT05889624","Responding With Evidence and Access for Childhood Headaches","Cognitive Behavioral Therapy Via Telehealth + Amitriptyline Compared to Cognitive Behavioral Therapy Via Telehealth: Pediatric Migraine Prevention (Responding With Evidence and Access for Childhood Headaches)","Inclusion Criteria:\n\n* Diagnosis: Migraine with or without aura that meets the International Classification of Headache Disorders (ICHD) criteria 5 or presentation of continuous headache that includes migranous episodes based upon headache history obtained by site PI or designee. (includes presentation with or without medication overuse headache as well)\n* Headache Frequency: 4 or more headache days based upon prospective headache diary of 28 days prior to randomization\n* Amitriptyline Eligible: Site PI or medical staff determined participant to be eligible for clinical prescription of amitriptyline as a preventive treatment for migraine\n* English fluency: Able to complete the study visits and questionnaires in English\n\nExclusion Criteria:\n\n* Current treatment includes amitriptyline and\u002For CBT specific to headache care\n* Current prescribed preventive antimigraine medication within a period equivalent to \\\u003C 5 half-lives of that medication before entering the baseline phase\n* Current treatment with onabotulinumtoxinA (Botox) or CGRP-based monoclonal antibody medications for migraine prevention\n* Youth who are pregnant\n* Report of current or ongoing suicidal thoughts. Suicide attempt within the past six months. History of bipolar disorder, prolonged QT, or pre-existing significant constipation or gastroparesis\n* Any and all other diagnoses or conditions which, in the opinion of the site investigator, would prevent the patient from being a suitable candidate for the study or interfere with the medical care needs of the participant",{"count":406,"type":21},400,[24],"This comparative effectiveness study will clarify current first-line preventive treatment approaches for use by neurologists, psychologists, and primary care providers in the context of real world care, and will demonstrate the feasibility of Cognitive Behavioral Therapy (CBT) via telehealth for youth with migraine. The focus is on applying evidence-based care and enhancing access to it. CBT via telehealth while taking a clinically-prescribed, pill-based prevention therapy (amitriptyline) will be compared to CBT via telehealth alone.",[28,105,106,107,108,109,110,111],[113,114,115,116,118,119,120,121,122],"2026-03-04",{"date":413,"type":36},"2026-03-06",{"date":415,"type":36},"2023-08-22",{"date":417,"type":21},"2027-12-31",{"name":130,"class":43},15,{"id":421,"slug":4,"hasResults":11,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":206,"enrollmentInfo":426,"targetDuration":4,"studyType":22,"phases":428,"briefSummary":430,"conditions":431,"keywords":441,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":70},"100521768","NCT06073886","Personalized Brain Stimulation to Treat Chronic Concussive Symptoms","Personalized Circuit-Based Frontoamygdala Neuromodulation for Persistent Post-Concussive Symptoms","Inclusion Criteria:\n\n* Mild traumatic brain injury (mTBI) defined in accord with the World Health Organization criteria in the last 12 months\n* age 18-65 at the time of the mTBI\n* high burden of post-concussive symptoms defined as a score \\>=20 on the Rivermead Post-Concussion Symptoms Questionnaire\n\nExclusion Criteria:\n\n* objective neurologic deficits\n* ongoing or prolonged (\\>3 months) post-concussive symptoms from a prior mTBI within 2 years of the index injury\n* history of transcranial magnetic stimulation (TMS) therapy\n* contraindications for TMS or magnetic resonance imaging (MRI) (e.g., metallic implant other than dental, pacemaker)\n* severe mental, physical, or medical problems that would impede participation or pose a risk for the planned intervention (e.g., liver, kidney, or heart disease, uncontrolled diabetes or hypertension, malignancy, psychosis, previous seizure, pregnancy)\n* active alcohol or illicit drug abuse\n* inability to speak and read English",{"count":427,"type":21},75,[429],"PHASE2","The goal of this study is to investigate a new treatment for chronic symptoms after concussion or mild traumatic brain injury in people aged 18-65 years old. Chronic symptoms could include dizziness, headache, fatigue, brain fog, memory difficulty, sleep disruption, irritability, or anxiety that occurred or worsened after the injury. These symptoms can interfere with daily functioning, causing difficulty returning to physical activity, work, or school. Previous concussion therapies have not been personalized nor involved direct treatments to the brain itself. The treatment being tested in the present study is a noninvasive, personalized form of brain stimulation, called transcranial magnetic stimulation (TMS).\n\nThe investigators intend to answer the questions:\n\n1. Does personalized TMS improve brain connectivity after concussion?\n2. Does personalized TMS improve avoidance behaviors and chronic concussive symptoms?\n3. Do the improvements last up to 2 months post-treatment?\n4. Are there predictors of treatment response, or who might respond the best?\n\nParticipants will undergo 14 total visits to University of California Los Angeles (UCLA):\n\n1. One for the baseline symptom assessments and magnetic resonance imaging (MRI)\n2. Ten for TMS administration\n3. Three for post-treatment symptom assessments and MRIs\n\nParticipants will have a 66% chance of being assigned to an active TMS group and 33% chance of being assigned to a sham, or inactive, TMS group. The difference is that the active TMS is more likely to cause functional changes in the brain than the inactive TMS.",[432,433,434,435,28,436,437,438,305,439,304,440],"Post-Concussion Syndrome","Concussion, Brain","Mild Traumatic Brain Injury","Head Injury","Dizziness","Cognitive Symptom","Dysautonomia","Irritability; Syndrome","Post-traumatic Stress Disorder",[442,443,444,445,446,447],"Transcranial Magnetic Stimulation","Magnetic Resonance Imaging","Functional MRI","Personalized neuromodulation","Amygdala","Prefrontal Cortex","2026-02-21",{"date":450,"type":36},"2026-02-24",{"date":452,"type":36},"2024-03-06",{"date":454,"type":21},"2027-01",{"name":456,"class":43},"University of California, Los Angeles",{"id":458,"slug":4,"hasResults":11,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":463,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":464,"targetDuration":4,"studyType":22,"phases":466,"briefSummary":467,"conditions":468,"keywords":480,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":492,"locationsCount":70},"100624078","NCT07404956","THE EFFECT OF SURGICAL MASK AND N95 MASK USE ON SURGICAL SMOKE IN OPERATING ROOM NURSES","COMPARISON OF THE EFFECTS OF SURGICAL MASK AND N95 MASK USE ON PHYSICAL SYMPTOMS OF SURGICAL SMOKE IN OPERATING ROOM","Inclusion Criteria:\n\n* Willingness to participate in the study\n* Aged 18 years or older\n* Working as a sterile operating room nurse at least 4 hours per day, 5 days per week\n* Compliance with the protocol requiring continuous use of both surgical mask and N95 mask for at least 4 hours per day\n* Ability to communicate verbally and provide informed consent\n\nExclusion Criteria:\n\n* Diagnosed psychiatric disorders\n* Presence of chronic respiratory, musculoskeletal, or neurological diseases\n* Presence of chronic dermatological conditions or allergies affecting the facial or respiratory area\n* Speech or communication impairments\n* Pregnancy\n* Holding a supervisory role (e.g., charge nurse) or non-sterile nursing role\n* Planned unit change or rotation during the study period",true,{"count":465,"type":21},38,[24],"This study was conducted to compare the effect of surgical mask and N95 mask use on physical symptoms due to surgical smoke in operating theatre nurses. The study, which was conducted in a single-group prospective quasi-experimental design, was completed with 38 nurses in the operating theatre unit of a state hospital in the Western Black Sea Region. Data were collected for four weeks using the Descriptive Information Form, Numerical Rating Scale and Symptom Follow-up Form. According to the findings, muscle weakness, myalgia in the upper extremities and muscle cramps were statistically significantly less in nurses using N95 masks. Respiratory parameters, watery eyes and redness were significantly lower in nurses using surgical masks. As a result, it was determined that the type of mask was effective on the incidence of physical symptoms related to surgical smoke.",[469,470,28,436,471,472,473,474,475,476,477,478,479],"Surgical Smoke Exposure","Occupational Exposure to Surgical Smoke","Nause and Vomiting","Fatigue Symptom","Eye Allergies","Abdominal Pain (AP)","Heart Rate Determination","SpO2","Muscle Weakness | Patient","Muscle Aches","Dispnea",[481,482,483,484],"Surgical Smoke","Masks","Operating Room Nurses","Occupational Exposure","2026-02-09",{"date":487,"type":36},"2026-02-12",{"date":489,"type":36},"2024-09-15",{"date":491,"type":21},"2026-02-28",{"name":493,"class":43},"Bartın Unıversity",{"id":495,"slug":4,"hasResults":11,"nctId":496,"briefTitle":497,"officialTitle":498,"acronym":499,"eligibilityCriteria":500,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":501,"targetDuration":4,"studyType":22,"phases":502,"briefSummary":503,"conditions":504,"keywords":506,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":516,"locationsCount":70},"100620740","NCT07361549","Localized Injection of Lidocaine Via the Middle Meningeal Artery for Intractable Headache Treatment","Localized Injection of Lidocaine Via the Middle Meningeal Artery for Intractable Headache Treatment: A Randomized, Double-Blinded, Parallel Phase 2 Clinical Trial","LIGHT 2","Inclusion Criteria:\n\n* Age 18 years or above\n* Referred for diagnostic angiography\n* Diagnosis of intractable migraine\n* Written informed consent able to be obtained from subject\n\nExclusion Criteria:\n\n* Baseline HIT-6 score less than 60 (severe)\n* Pregnant, breastfeeding, or unwilling to practice contraception during participation in the study\n* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data\n* Concomitant intracranial pathology (eg, intracranial malignancy)\n* Known hypersensitivity and\u002For contraindication to lidocaine or local anesthetics of the amide type\n* Taking chronic medications that, when co-administered with lidocaine and other local anesthetics, are at increased risk of developing methemoglobinemia (nitrates\u002Fnitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, acetaminophen, metoclopramide, quinine, sulfasalazine)\n* Known contraindications for angiography (eg, ESRD not requiring hemodialysis). Patients with contrast allergy with be premeditated with diphenhydramine and steroids.\n* Contraindication to anesthetic agents used for conscious sedation\u002Fmonitored anesthesia care (MAC)\n* Concurrent participation in another research protocol for investigation of an experimental therapy\n* Per DSA imaging, presence of a cerebrovascular pathology known to cause headache (eg, arteriovenous malformation, dural arteriovenous fistula)\n* Per DSA imaging, presence of anastomosis or anatomical variation (eg, branches of middle meningeal artery) that could lead to increased procedural risk\n* Per DSA imaging, lack of endovascular access to either middle meningeal artery, or origin of the middle meningeal artery other than from the external carotid artery\n* Known or suspected inability to adhere to study protocol or protocol requirements, as per discretion of the Investigator or treating provider",{"count":20,"type":21},[429],"The goal of this clinical trial is to test whether injecting lidocaine into two blood vessels of the brain can help treat chronic headaches (migraines)",[505,28],"Refractory Migraine",[113,114,507,508],"lidocaine","middle meningeal artery","2026-01-21",{"date":511,"type":36},"2026-01-23",{"date":513,"type":21},"2026-03",{"date":515,"type":21},"2031-07",{"name":517,"class":43},"Daniel A Tonetti, MD",{"id":519,"slug":4,"hasResults":11,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":4,"eligibilityCriteria":523,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":524,"enrollmentInfo":525,"targetDuration":4,"studyType":22,"phases":526,"briefSummary":527,"conditions":528,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":70},"100615554","NCT07294118","Infusion of Lidocaine and Steroids in Middle Meningeal Artery for Pain in Subarachnoid Hemorrhage","Endovascular Infusion of Lidocaine and Steroids in the Middle Meningeal Artery for Pain Management in Spontaneous Subarachnoid Hemorrhage Patients","Inclusion Criteria:\n\n* Age ≥18 years.\n* Diagnosed with aneurysmal SAH, Hunt and Hess Grades 1-2.\n* Consent to study procedures and follow-up evaluations.\n\nExclusion Criteria:\n\n* Known allergies to lidocaine or steroids.\n* Arteriovenous malformations.\n* Dural Arteriovenous Fistulas.\n* Other significant intracranial pathologies.\n* Hemodynamic instability preventing safe intervention.\n* Previous MMA interventions.\n* Previous craniotomies or need for craniotomy.\n* Need for external ventricular drain.","100 Years",{"count":419,"type":21},[429],"The goal of this clinical trial is to learn if an infusion of lidocaine, with or without steroids, into the middle meningeal artery (MMA) helps relieve severe headaches in patients with spontaneous subarachnoid hemorrhage (SAH). It will also study the safety of this treatment.",[529,28,530,531],"Subarachnoid Hemorrhage, Aneurysmal","Opiate Dependence","Opioid Use","2026-01-07",{"date":534,"type":36},"2026-01-09",{"date":536,"type":36},"2026-01-02",{"date":538,"type":21},"2027-08",{"name":540,"class":43},"The University of Texas Medical Branch, Galveston",{"id":542,"slug":4,"hasResults":11,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":4,"eligibilityCriteria":546,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":206,"enrollmentInfo":547,"targetDuration":4,"studyType":22,"phases":549,"briefSummary":550,"conditions":551,"keywords":566,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":574,"locationsCount":70},"100619143","NCT07340788","Amylin-Induced Migraine Attacks Without Aura","Amylin-Induced Migraine Attacks Without Aura: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 to 65 years of age upon entry into screening\n* A body weight of 50 to 100 kg\n* History of migraine without aura for ≥12 months and in accordance with ICHD-3\n* Between 1-5 monthly migraine days without aura on average across the 3 months prior to screening\n* Provision of informed consent prior to initiation of any study-specific activities\u002Fprocedures\n\nExclusion Criteria:\n\n* Any history of a primary or secondary headache disorder other than migraine without aura and infrequent episodic tension-type headache\n* Any history of moderate to severe traumatic brain injury\n* Any history of cardiovascular disease, including cerebrovascular diseases\n* Any history of pulmonary disease\n* Any other clinically significant disorders, conditions, or diseases that might impact the safety of the subject or interfere with the study's evaluation, procedures, or completion, aside from those mentioned above. This includes any relevant medical history or evidence that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results\n* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior\n* Female subjects of childbearing potential with a positive pregnancy test during any study visit\n* Cardiovascular disease of any kind, including cerebrovascular diseases\n* Hypertension (systolic blood pressure of ≥150 mmHg and\u002For diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day\n* Hypotension (systolic blood pressure of ≤90 mmHg and\u002For diastolic blood pressure of ≤50 mmHg)\n* Abnormalities on the electrocardiogram that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results\n* Daily use of any medication other than contraceptives\n* Intake of any medication other than contraceptives within 48 hours of infusion start\n* Intake of caffeine, nicotine, and alcohol within 12 hours of infusion start\n* Headache of any intensity within 48 hours of infusion start\n* Migraine attack within 48 hours of infusion start\n* Aura within 48 hours of infusion start",{"count":548,"type":21},21,[24],"Pramlintide is a peptide analogue of human amylin which is a vasoactive signaling molecule involved in the pathogenesis of migraine. This study investigates whether pramlintide induces migraine attacks without aura in people with migraine without aura.",[237,105,552,553,554,555,556,557,108,28,558,559,560,561,562,563,564,565],"Brain Diseases","Nervous System Diseases","Central Nervous System Diseases","Neurologic Manifestations","Signs and Symptoms","Pathological Conditions, Signs and Symptoms","Pain","Peptide Hormones","Hormones","Hormones, Hormone Substitutes, and Hormone Antagonists","Peptides","Amino Acids, Peptides, and Proteins","Amylin","Pramlintide",[107,28,558,564],"2026-01-05",{"date":569,"type":36},"2026-01-14",{"date":571,"type":21},"2026-02",{"date":573,"type":21},"2028-10-30",{"name":575,"class":43},"Danish Headache Center",{"id":577,"slug":4,"hasResults":11,"nctId":578,"briefTitle":579,"officialTitle":579,"acronym":580,"eligibilityCriteria":581,"healthyVolunteers":11,"sex":16,"minAge":582,"maxAge":277,"enrollmentInfo":583,"targetDuration":98,"studyType":299,"phases":4,"briefSummary":585,"conditions":586,"keywords":588,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":70},"100613666","NCT07269561","Headache Registration and Followup Initiated by Tongji Hospital, HUST","HEALTH","Inclusion Criteria:\n\n* Meeting the diagnostic criteria for headache classification according to the International Classification of Headache Disorders 3rd edition (ICHD-3, 2018) Age between 6-70 years Voluntary participation with consent Good compliance with follow-up and questionnaire surveys\n\nExclusion Criteria:\n\n* Complex headache etiology, e.g., presence of ≥3 distinct factors causing headache Presence of severe systemic diseases or life expectancy less than 10 years Significant cognitive or psychiatric issues that prevent completion of questionnaire follow-ups and clinical assessments","6 Years",{"count":584,"type":21},50000,"Headache is one of the most common chief complaints in clinical practice, with a high global prevalence rate. It may originate from a primary headache disorder or manifest as a clinical symptom of various diseases due to the complexity of its triggers, specific types, diagnosis, and treatment which present significant challenges. As people's life pace continues to accelerate and psychological and physiological pressures increase, many patients experience headache symptoms, leading to a growing number of patients seeking treatment in neurology departments. The increasing incidence of headache conditions has resulted in a decline in patients' quality of life.\n\nTherefore, this research is part of Hubei Province's major project \"Discovery and Functional Research of Major Disease Targets Based on Genetic Big Data.\" The study aims to establish a clinical cohort and develop a precise diagnosis and treatment system for headaches. This system will collect the history of headache sufferers, record the real-world treatment data, and incorporate sample banks, multi-dimensional databases, pre-clinical drug evaluation platforms, and clinical efficacy precise dynamic monitoring models through immunotherapy and other cutting-edge biotechnologies, multi-omics detection technologies, and big data bioinformatics analysis technologies.\n\nThe system will provide scientists and clinicians with auxiliary diagnostic and treatment decision support, offer reliable screening targets for early headache diagnosis and drug development companies, accelerate the latest headache diagnosis and targeted treatment, and achieve breakthrough advances in headache prevention and cure.",[28,587],"Comorbidities",[28,589,590,591,592],"prediction models","database","cohort","Real world observation","2025-11-26",{"date":595,"type":36},"2025-12-08",{"date":597,"type":36},"2024-01-01",{"date":599,"type":21},"2028-12-31",{"name":601,"class":43},"Tongji Hospital",{"id":603,"slug":4,"hasResults":11,"nctId":604,"briefTitle":605,"officialTitle":606,"acronym":607,"eligibilityCriteria":608,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":609,"enrollmentInfo":610,"targetDuration":4,"studyType":22,"phases":612,"briefSummary":613,"conditions":614,"keywords":615,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":617,"lastUpdatePostDateStruct":618,"startDateStruct":620,"completionDateStruct":622,"leadSponsor":624,"locationsCount":626},"100516766","NCT06008795","BLOCK-SAH - PPF-Block for Post-SAH Headache","Pterygopalatine Fossa (PPF) Block as an Opioid Sparing Treatment for Acute Headache in Spontaneous Subarachnoid Hemorrhage","BLOCK-SAH","In order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Provision of signed and dated ICF by participant or a legally authorized representative (LAR)\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Male or female, aged ≥18 and ≤ 85 years\n4. Admitted with a primary diagnosis of spontaneous, non-traumatic, SAH within 72 hours of ictus hemorrhage\n5. Disease-specific inclusion criteria:\n\n   1. Spontaneous, non-traumatic SAH\n   2. Subarachnoid pattern of hemorrhage warranting diagnostic DSA due to involvement of at least one of the following regions: quadrigeminal plate, prepontine cistern, perimesencephalic cistern, Sylvian fissure, or surrounding Circle of Willis\n   3. Modified Fisher grade 1-4 (on presentation imaging)\n   4. Hunt and Hess 1-3 or World Federation of Neurosurgeons grade 1-4 (on screening, included only if also fulfilling Glasgow Coma Scale verbal subscore ≥4)\n   5. Minimum Glasgow Coma Scale verbal subscore of 4 (on screening)\n6. Able to verbalize pain scale scores according to 11-point numeric pain scale\n\n   In order to be enrolled and undergo randomization in this study, an individual must meet all of the additional criteria:\n7. Stabilization period criteria:\n\n   1. A minimum of 4 hours from DSA with clipping or coiling procedure (whenever applicable)\n   2. Successful treatment of culprit vascular lesion (i.e., ≥90% obliteration of aneurysm), when applicable\n8. Requiring a minimum of 15mg OME prn for headache analgesia during any 24-hour period during eligibility period\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Premorbid conditions:\n\n   1. Pre-existing neurologic, psychiatric, or other condition that would confound neurologic assessment or would make difficult\u002Fimpossible to accurately assess neurologic and\u002For functional outcome\n   2. Pre-existing diffuse flow-limiting narrowing of arteries in the Circle of Willis, regardless of etiology (e.g., atherosclerosis, vasculitis, Moya-Moya syndrome)\n   3. Prior use of opioid or barbiturate analgesics for at least two-thirds of the days in previous month, regardless of indication\n   4. Diagnosis of substance use disorder in the previous year\n   5. Infected or wounded skin, or a skin lesion at the site of puncture for PPF- injection\n2. Uncorrected coagulopathy\n\n   1. Platelet count \\\u003C 50,000\u002FμL, International Normalized Ratio (INR) \\> 1.7\n   2. Requiring use of systemic anticoagulation and antiplatelet therapy (except for aspirin monotherapy).\n3. SAH-specific:\n\n   1. Head trauma as etiology of SAH\n   2. Infection as cause for aneurysm or SAH (i.e., mycotic aneurysms)\n   3. Inability to successfully treat culprit vascular lesion\n   4. Diffuse vasospasm on pre-enrollment diagnostic CTA or DSA. Vasospasm is defined as moderate-to-severe arterial narrowing on DSA or CTA not attributable to atherosclerosis, catheter-induced spasm, or vessel hypoplasia, as determined by a neuroradiologist or neurointerventionalist\n4. Standard pain regimen conditions\n\n   1. Elevation of hepatic enzymes prohibiting use of scheduled APAP (i.e., AST or ALT \\> 3x upper limit level)\n   2. Chronic liver condition with absolute contra-indication for APAP (even at lower maximum daily doses)\n5. Participation in a concurrent investigational\u002Finterventional study (observational studies allowed)\n6. Known to be pregnant, or with a positive pregnancy test\n7. Allergy or intolerance to the medications used in the PPF-block (i.e., ropivacaine, dexamethasone) or standard pain regimen (APAP)\n8. Vulnerable populations such as prisoners and inmates (abiding GCP per the study IRB)\n9. Unable to receive first PPF-injection within 96 hours of ictus hemorrhage","85 Years",{"count":611,"type":21},195,[429],"BLOCK-SAH is a phase II, multicenter, randomized, double-blinded, placebo-controlled clinical trial with a sequential parallel comparison design (SPCD) of bilateral pterygopalatine fossa (PPF) injections with 20mg ropivacaine + 4mg dexamethasone (active, PPF-block) compared to saline (placebo) for headache in survivors of aneurysmal subarachnoid hemorrhage (SAH), while monitoring intracranial arterial mean flow velocities with transcranial Doppler (TCD) peri-intervention (intervention = PPF-injections: active or placebo)",[529,28],[616],"Pterygopalatine Fossa Nerve Block","2025-11-25",{"date":619,"type":36},"2025-11-28",{"date":621,"type":36},"2023-12-17",{"date":623,"type":21},"2027-02-28",{"name":625,"class":43},"University of Florida",11,{"id":628,"slug":4,"hasResults":11,"nctId":629,"briefTitle":630,"officialTitle":630,"acronym":4,"eligibilityCriteria":631,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":524,"enrollmentInfo":632,"targetDuration":4,"studyType":22,"phases":634,"briefSummary":635,"conditions":636,"keywords":638,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":642,"lastUpdatePostDateStruct":643,"startDateStruct":644,"completionDateStruct":646,"leadSponsor":648,"locationsCount":70},"100563835","NCT06621329","Transnasal Sphenopalatine Ganglion Block for Treatment of Acute Subarachnoid Hemorrhage Associated Headache","Inclusion Criteria:\n\n* Acute subarachnoid hemorrhage\n* Age greater than 18 years\n* Secured aneurysm\n* Patient can verbalize pain score to clinician, nurse, medical translator, or surrogate decision\n* maker\n* Patient or surrogate decision maker is available to consent\n\nExclusion Criteria:\n\n* Less than 18 years old\n* Unsecured aneurysm\n* Pregnant or lactating\n* Prisoner\n* Unable to verbalize pain score to clinician, nurse, medical translator, or surrogate decision maker\n* Nasal or facial trauma or surgery within the last three months\n* Allergy to lidocaine, bupivacaine, or dexamethasone\n* Patient is unable to consent and no available surrogate decision maker",{"count":633,"type":21},40,[429,56],"The study titled \\"Transnasal sphenopalatine ganglion block for treatment of acute subarachnoid hemorrhage associated headache\\" is a randomized controlled pilot study aimed at evaluating the efficacy of a transnasal sphenopalatine ganglion (SPG) block in addition to standard pain medication for reducing headache severity in patients with acute subarachnoid hemorrhage (aSAH). The study also examines whether this intervention can reduce opioid requirements during hospitalization and upon discharge.",[637,28],"SAH (Subarachnoid Hemorrhage)",[639,640,641,189,113],"aSAH","peripheral nerve block","sphenopalatine ganglion","2025-11-24",{"date":593,"type":36},{"date":645,"type":36},"2024-10-17",{"date":647,"type":21},"2026-10",{"name":649,"class":43},"University of California, Davis",{"id":651,"slug":4,"hasResults":11,"nctId":652,"briefTitle":653,"officialTitle":654,"acronym":655,"eligibilityCriteria":656,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":657,"enrollmentInfo":658,"targetDuration":4,"studyType":22,"phases":659,"briefSummary":660,"conditions":661,"keywords":663,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":667,"lastUpdatePostDateStruct":668,"startDateStruct":670,"completionDateStruct":672,"leadSponsor":674,"locationsCount":44},"100600461","NCT07097792","Concussion Recovery and Support Program","Pilot Study of Concussion Recovery and Support Program (CRISP)","CRISP","Inclusion Criteria:\n\n* Diagnosed with a concussion and at least 2 weeks from injury but less than two years.\n* New or worsening headache since concussion\n* Had at least one day with headache last week of moderate severity or two days with headache of any severity\n\nExclusion Criteria:\n\n* Non-English speaking\n* Chronic medical illness\u002F medical complexity\n* Housing instability\n* Acute mental health issues such as active suicidality, psychiatric hospitalization within the past 6 months, ER visit for suicidality in the past 6 months or experiencing psychosis or delusions","29 Years",{"count":633,"type":21},[24],"Pilot randomized controlled trial (RCT) comparing a novel intervention Concussion Recovery and Support Program (CRISP) for adolescents and young adults (AYA) 18-29 yo with concussion\u002F mild TBI.",[662,434,28],"Brain Concussion",[664,665,666],"mental health","therapy","emotional awareness and expression therapy","2025-11-14",{"date":669,"type":36},"2025-11-18",{"date":671,"type":36},"2025-10-13",{"date":673,"type":21},"2026-07-31",{"name":675,"class":43},"Seattle Children's Hospital",{"id":677,"slug":4,"hasResults":11,"nctId":678,"briefTitle":679,"officialTitle":680,"acronym":4,"eligibilityCriteria":681,"healthyVolunteers":463,"sex":16,"minAge":17,"maxAge":682,"enrollmentInfo":683,"targetDuration":4,"studyType":22,"phases":684,"briefSummary":686,"conditions":687,"keywords":689,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":694,"lastUpdatePostDateStruct":695,"startDateStruct":697,"completionDateStruct":699,"leadSponsor":701,"locationsCount":70},"100524696","NCT06112093","Repetitive Transcranial Magnetic Stimulation for Post-concussion Headaches","Using Repetitive Transcranial Magnetic Stimulation to Manage Headaches and Improve Rehabilitation Outcomes in Mild Traumatic Brain Injury: A Longitudinal Study","Inclusion Criteria:\n\n* 18 - 55 years old\n* mTBI with loss of consciousness for less than 30 min, initial Glasgow Coma Scale between 13 and 15, or post-traumatic amnesia for ≤ 24 hours\n* diagnosis of persistent post-traumatic headache according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria\n* headache develops within 7 days after head trauma\n* headache persists for \\>=3 months after head trauma despite receiving standard care\n* average persistent headache intensity is \\>= 3\u002F10 of the numerical rating scale (NRS) on \\>=3days\u002Fweek\n* no evidence of radiculopathy or peripheral neuropathy on electromyography or clinical evaluation\n* no evidence of other possible causes of headaches\n\nExclusion Criteria:\n\n* history of chronic headache diagnoses such as migraine, tension, or cluster headaches prior to the incidence of mTBI\n* history of other neurologic conditions with medications affecting the central nervous system\n* contraindications of receiving TMS (e.g., a history of epileptic seizure and having implants like a cardiac pacemaker or intracerebral vascular clip","55 Years",{"count":161,"type":21},[685],"PHASE1","This study aims to examine the long-term effect of repetitive transcranial magnetic stimulation (rTMS), a non-invasive brain stimulation technique, on chronic headaches following mild traumatic brain injury (mTBI). rTMS has been shown to be effective in reducing chronic headaches without side effects commonly seen in medications, such as sleepiness and addiction. This study uses rTMS to manage chronic headaches to improve post-concussion symptoms and reduce the economic burden due to delayed recovery. This project aims to better identify biomarkers for diagnosis and prognosis and maximize recovery from mTBI.",[662,434,28,688],"Post-Concussion Symptoms",[690,691,307,692,693],"Repetitive transcranial magnetic stimulation","Non-invasive brain stimulation","Chronic pain","Biomarkers","2025-10-08",{"date":696,"type":36},"2025-10-10",{"date":698,"type":36},"2023-10-23",{"date":700,"type":21},"2027-10-23",{"name":702,"class":43},"State University of New York - Upstate Medical University",""]